Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$61 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-17 Mln
ROE
-1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.7
Industry P/E
--
EV/EBITDA
4.7
Div. Yield
0 %
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
107,821,231
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Impact BioMedical, Inc (IBO)
| -- | 35.8 | -- | -28.0 | -- | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Impact BioMedical, Inc (IBO)
|
0.6 | 60.9 | 0.0 | -11.8 | -13,343.8 | -140.4 | -- | 6.7 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products... in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc Read more
CFO. Secretary & Treasurer
Mr. Todd D. Macko
Chairman & CEO
Mr. Frank D. Heuszel Esq., J.D.
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Impact BioMedical, Inc (IBO) is $0.59 (NYSE) as of 02-Apr-2026 15:59 EDT. Impact BioMedical, Inc (IBO) has given a return of -27.98% in the last 1 years.
Since, TTM earnings of Impact BioMedical, Inc (IBO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-8.13
|
3.92
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
-6.41
|
8.42
|
The 52-week high and low of Impact BioMedical, Inc (IBO) are Rs 1.95 and Rs 0.36 as of 03-Apr-2026.
Impact BioMedical, Inc (IBO) has a market capitalisation of $ 61 Mln as on 27-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Impact BioMedical, Inc (IBO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.16
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.